Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYATM (tildrakizumab-asmn) in patients with active psoriatic arthritis that was presented in a late-breaking oral presentation at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain (abstract #LB-0002).1 The interim analysis revealed that over 71 percent of patients treated with ILUMYA™ experienced a 20 percent improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study. The interim results showed ILUMYA™ was well tolerated with a low rate of serious treatment-emergent adverse events.
ILUMYA™ is approved in the U.S. for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and is being investigated for psoriatic arthritis. Psoriatic arthritis, which affects up to 42 percent of people with plaque psoriasis, is an inflammatory condition that impacts both the joints and skin. It is painful, causes fatigue, and can lead to swelling and stiffness of the joints that may reduce range of motion. If left untreated, this chronic condition can lead to permanent joint damage.2,3,4
"As a researcher and clinician, it's encouraging to see these improvements in pain, joint swelling and skin plaques. Our interim findings showed that about half of the patients treated with 100 mg or 200 mg of tildrakizumab saw a 50 percent improvement in psoriatic arthritis symptoms and about a quarter saw a 70 percent improvement within 24 weeks," said study investigator Philip J. Mease, MD, MACR, director of rheumatology research at the Swedish Medical Center/Providence St Joseph Health and clinical professor at the University of Washington School of Medicine, Seattle, WA. "These data insights are promising for patients who continue to struggle with the impact psoriatic arthritis has on their daily lives."
The Phase 2 study interim results showed that across all patients receiving ILUMYA™, 75.3 percent experienced a 20 percent improvement in symptoms of psoriatic arthritis (ACR20) at week 24 compared to 50.6 percent of patients on placebo. The findings were similar in patients receiving 100mg or 200 mg of ILUMYA™ on a quarterly dosing schedule. For some patients on 100 mg ILUMYA™, results were seen as early as 8 weeks. Furthermore, an average of 47.1 percent of all patients receiving ILUMYA™ achieved an ACR50 response with some results seen as early as 12 weeks, compared to 24.1 percent of patients on placebo.
The interim results also showed ILUMYA™ was well tolerated with a low and comparable rate of adverse events to placebo. Serious treatment-emergent adverse events occurred in 2.2 percent of patients treated with ILUMYA™ and 2.5 percent in those on placebo, with no patients discontinuing treatment due to these events. The most common adverse events through week 24 included common cold (nasopharyngitis), upper respiratory tract infection, and headache. There were no reports of candidiasis, inflammatory bowel disease, major adverse cardiac events, malignancy, or deaths.
"We are committed to the continued clinical development of ILUMYA™ and are pleased with the interim results in our first study for psoriatic arthritis," said Kyle Ferguson, Business Unit Head, Vice President Sales & Marketing, Sun Pharma. "To help us determine the potential of ILUMYA™ across psoriatic disease, we are now exploring a possible Phase 3 trial for psoriatic arthritis with regulatory authorities."
Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.390.1 as compared to the previous close of Rs. 391.65. The total number of shares traded during the day was 193543 in over 2692 trades.
The stock hit an intraday high of Rs. 393.6 and intraday low of 385.7. The net turnover during the day was Rs. 75306141.